- Home
- » Tags
- » Protein kinase inhibitor
Top View
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- Spotlight on Midostaurin in the Treatment of FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis: Design, Development, and Potential Place in Therapy
- Nexavar, INN-Sorafenib
- A Compendium of Tyrosine-Kinase Inhibitors: Powerful and Efficient Drugs Against Cancer Costa, D
- Exploring Receptor Tyrosine Kinases-Inhibitors in Cancer
- Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
- Crenolanib Is a Type I Tyrosine Kinase Inhibitor That Inhibits Mutant KIT D816 Isoforms Prevalent in Systemic Mastocytosis and Core Binding Factor Leukemia
- Kinase Inhibitors: a New Class of Antirheumatic Drugs
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- PI3 Kinase Inhibitors in the Clinic: an Update
- Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
- Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB
- Auspar Attachment : Product Information for Iclusig (Ponatinib)
- 3 Kinase Inhibitor Drugs
- Selective DNA-Pkcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy
- The London School of Economics and Political Science Cancer Medicines
- Tepzz¥ 8__ 7A T
- Inhibitory Effects of the Tyrosine Kinase Inhibitor Genistein on Mammalian DNA Topoisomerase II1
- Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments
- Functional Genomic Screening Identifies Dual Leucine Zipper Kinase
- Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia
- DNA-Dependent Protein Kinase Inhibitors As Drug Candidates for the Treatment of Cancer
- Tyrosine Kinase Inhibitors As Novel Target for Treatment of Cancer
- Cyclin-Dependent Protein Kinase Inhibitors Including Palbociclib As
- KMU-1170, a Novel Multi-Protein Kinase Inhibitor, Suppresses
- Clinical Considerations for the Use of FLT3 Inhibitors in Acute Myeloid Leukemia T ⁎ Taylor M
- Dose Intensity for Induction in Acute Myeloid Leukemia: What, When, and for Whom? by Shannon R
- Pharmacology Review(S) Memorandum
- TAGRISSO 40 Mg Film-Coated Tablets TAGRISSO 80 Mg Film-Coated Tablets
- Compounds from Natural Sources As Protein Kinase Inhibitors
- Protein Tyrosine Kinase/RTK
- Repurposing Libraries of Eukaryotic Protein Kinase Inhibitors for Antibiotic Discovery
- Oncology Oral, Hematologic Cancers Therapeutic Class Review (TCR)
- Drugging Protein Kinases in Cancer: from Small Molecules to Nanoparticles
- Magic Bullets for Protein Kinases
- Midostaurin: an Emerging Treatment for Acute Myeloid Leukemia Patients
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
- Dual Protein Kinase and Nucleoside Kinase Modulators for Rationally Designed Polypharmacology
- Classification of Small Molecule Protein Kinase Inhibitors Based
- Chronic Lymphocytic Leukaemia (CLL) - Starting Active Treatment
- Health Policy and Community Pharmacy Provision of Oncology
- Screening the Human Kinome:Layout 1 1/7/08 09:33 Page 21
- Topoisomerase I Inhibitors: Camptothecins and Beyond
- Kinase Inhibitors As Potential Agents in the Treatment of Multiple Myeloma
- Protein Kinases As Drug Targets
- Mrna Median Score Name Description 1 99.7 Etoposide
- Protein Tyrosine Kinase/RTK
- Dynamically Committed, Uncommitted, and Quenched States Encoded in Protein Kinase a Revealed by NMR Spectroscopy
- Studies on Selectivity Determinants of Protein Kinase Inhibitor Binding